The US Food and Drug Administration continues to promote the use of active-controlled, non-inferiority trial designs in rheumatoid arthritis, but sponsor uptake has not been enthusiastic, speakers indicated at a recent virtual summit sponsored by the FDA and the American College of Rheumatology.
Rheumatoid arthritis was one of the first indications to benefit from the evolution of the immunology pharmacopoeia from disease-modifying antirheumatic drug warhorses to include new mechanisms in both small molecules...